During the past decade, Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 6 clinical trials were completed, i.e. on average, 85.7% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku" #1 sponsor was "Pfizer" with 3 trials, followed by "Celgene" with 2 trials sponsored, "Kartos Therapeutics, Inc." with 2 trials sponsored, "ADC Therapeutics S.A." with 1 trials sponsored and "Gilead Sciences" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku" #1 collaborator was "UCB Pharma" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku" are "Mantle Cell Lymphoma" (2 trials), "Acute Lymphoblastic Leukemia" (1 trials), "Acute Myeloid Leukemia" (1 trials), "Acute-graft-versus-host Disease" (1 trials) and "Chronic Lymphocytic Leukemia" (1 trials). Many other conditions were trialed in "Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku" in a lesser frequency.

Most popular intervention types in "Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku" are "Drug" (11 trials), "Biological" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "KRT-232" (2 trials), "Lenalidomide" (2 trials), "Placebo" (2 trials), "Bendamustine" (1 trials) and "Best Available Therapy (BAT)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku" are 12 trials for "All" genders.

Currently, there are NaN active trials in "Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".